开云app官网登录入口网页版-官方正版

[GetPortalCommentsPageByObjectIdResponse(id=2226178, encodeId=80e922261e84f, content=感觉这个期刊录用率只有1/8<a href='/topic/show?id=fe61688e88d' target=_blank style='color:#2F92EE;'>#生信#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68878, encryptionId=fe61688e88d, topicName=生信)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Tue Sep 17 09:53:34 CST 2024, time=2024-09-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2222643, encodeId=0060222264320, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：分子生物 经验分享：all reviews complete要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7df6548400, createdName=ms2000000368944021, createdTime=Tue Aug 27 12:01:03 CST 2024, time=2024-08-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2197148, encodeId=4d91219e148fc, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：生态学 经验分享：2023年8月投稿 2023年11月第一轮给了大修 2024年2月28日修回 2024年3月20日pre-accept 2024年3月26日格式修改修回 2024年4月1日 with editor。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce406162649, createdName=ms6000000307870975, createdTime=Sat Apr 06 17:20:10 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2097728, encodeId=dd63209e7287c, content=审稿速度:6.0 经验分享：7.14投的，快三个月了，还没修回意见，太慢了，捉急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb028255336, createdName=ms6000000988225388, createdTime=Tue Nov 01 03:41:58 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2218386, encodeId=4487221838675, content=偏重的研究方向：免疫学;医学综合 经验分享：iscience和biomed pharma，或者life science相比，哪个会更好些, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sun Aug 04 08:29:43 CST 2024, time=2024-08-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2218255, encodeId=e040221825573, content=偏重的研究方向：免疫学;生物大分子;医学综合 经验分享：iScience在with editor之后的状态是什么？直接是Under Review？有没有投过综述的大佬？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sat Aug 03 09:46:04 CST 2024, time=2024-08-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2208012, encodeId=4e6122080127a, content=审稿速度:1.0 经验分享：投eClinicalMedicine被transfer到iScience，2天送审，2周all reviews complete, 当天major revision，自认为是10分左右的水平，感觉投这个有些亏，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Mon Jun 03 09:34:00 CST 2024, time=2024-06-03, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2214702, encodeId=e1f52214e026c, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;药物 经验分享：2024.4.28投稿，2024.6.6给了大修，两个审稿人，给了20个左右意见，让补meta，2024.6.23修回，2024.7.8小修，只有一个审稿人提了一个小问题，2024.7.11修回，2024.7.13all reviews complete，等待ing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1426565191, createdName=ms4000000921584140, createdTime=Sat Jul 13 08:24:35 CST 2024, time=2024-07-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2211673, encodeId=c2fc22116e3a2, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：记得当初说是对比nc和sa的综合性期刊，现在怎么看怎么像个骗局，连communications xx系列都比不上。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Wed Jun 26 08:15:16 CST 2024, time=2024-06-26, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2210803, encodeId=72da22108032d, content=2023年IF 4.6分。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Thu Jun 20 14:07:08 CST 2024, time=2024-06-20, status=1, ipAttribution=湖北省)]

2024-09-17 ms3000000851999119 来自北京

感觉这个期刊录用率只有1/8#生信#

2 0

[GetPortalCommentsPageByObjectIdResponse(id=2226178, encodeId=80e922261e84f, content=感觉这个期刊录用率只有1/8<a href='/topic/show?id=fe61688e88d' target=_blank style='color:#2F92EE;'>#生信#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68878, encryptionId=fe61688e88d, topicName=生信)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Tue Sep 17 09:53:34 CST 2024, time=2024-09-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2222643, encodeId=0060222264320, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：分子生物 经验分享：all reviews complete要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7df6548400, createdName=ms2000000368944021, createdTime=Tue Aug 27 12:01:03 CST 2024, time=2024-08-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2197148, encodeId=4d91219e148fc, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：生态学 经验分享：2023年8月投稿 2023年11月第一轮给了大修 2024年2月28日修回 2024年3月20日pre-accept 2024年3月26日格式修改修回 2024年4月1日 with editor。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce406162649, createdName=ms6000000307870975, createdTime=Sat Apr 06 17:20:10 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2097728, encodeId=dd63209e7287c, content=审稿速度:6.0 经验分享：7.14投的，快三个月了，还没修回意见，太慢了，捉急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb028255336, createdName=ms6000000988225388, createdTime=Tue Nov 01 03:41:58 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2218386, encodeId=4487221838675, content=偏重的研究方向：免疫学;医学综合 经验分享：iscience和biomed pharma，或者life science相比，哪个会更好些, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sun Aug 04 08:29:43 CST 2024, time=2024-08-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2218255, encodeId=e040221825573, content=偏重的研究方向：免疫学;生物大分子;医学综合 经验分享：iScience在with editor之后的状态是什么？直接是Under Review？有没有投过综述的大佬？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sat Aug 03 09:46:04 CST 2024, time=2024-08-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2208012, encodeId=4e6122080127a, content=审稿速度:1.0 经验分享：投eClinicalMedicine被transfer到iScience，2天送审，2周all reviews complete, 当天major revision，自认为是10分左右的水平，感觉投这个有些亏，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Mon Jun 03 09:34:00 CST 2024, time=2024-06-03, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2214702, encodeId=e1f52214e026c, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;药物 经验分享：2024.4.28投稿，2024.6.6给了大修，两个审稿人，给了20个左右意见，让补meta，2024.6.23修回，2024.7.8小修，只有一个审稿人提了一个小问题，2024.7.11修回，2024.7.13all reviews complete，等待ing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1426565191, createdName=ms4000000921584140, createdTime=Sat Jul 13 08:24:35 CST 2024, time=2024-07-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2211673, encodeId=c2fc22116e3a2, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：记得当初说是对比nc和sa的综合性期刊，现在怎么看怎么像个骗局，连communications xx系列都比不上。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Wed Jun 26 08:15:16 CST 2024, time=2024-06-26, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2210803, encodeId=72da22108032d, content=2023年IF 4.6分。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Thu Jun 20 14:07:08 CST 2024, time=2024-06-20, status=1, ipAttribution=湖北省)]

2024-08-27 ms2000000368944021 来自湖南省

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：分子生物
经验分享：all reviews complete要多久呀

0 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2226178, encodeId=80e922261e84f, content=感觉这个期刊录用率只有1/8<a href='/topic/show?id=fe61688e88d' target=_blank style='color:#2F92EE;'>#生信#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68878, encryptionId=fe61688e88d, topicName=生信)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Tue Sep 17 09:53:34 CST 2024, time=2024-09-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2222643, encodeId=0060222264320, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：分子生物 经验分享：all reviews complete要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7df6548400, createdName=ms2000000368944021, createdTime=Tue Aug 27 12:01:03 CST 2024, time=2024-08-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2197148, encodeId=4d91219e148fc, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：生态学 经验分享：2023年8月投稿 2023年11月第一轮给了大修 2024年2月28日修回 2024年3月20日pre-accept 2024年3月26日格式修改修回 2024年4月1日 with editor。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce406162649, createdName=ms6000000307870975, createdTime=Sat Apr 06 17:20:10 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2097728, encodeId=dd63209e7287c, content=审稿速度:6.0 经验分享：7.14投的，快三个月了，还没修回意见，太慢了，捉急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb028255336, createdName=ms6000000988225388, createdTime=Tue Nov 01 03:41:58 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2218386, encodeId=4487221838675, content=偏重的研究方向：免疫学;医学综合 经验分享：iscience和biomed pharma，或者life science相比，哪个会更好些, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sun Aug 04 08:29:43 CST 2024, time=2024-08-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2218255, encodeId=e040221825573, content=偏重的研究方向：免疫学;生物大分子;医学综合 经验分享：iScience在with editor之后的状态是什么？直接是Under Review？有没有投过综述的大佬？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sat Aug 03 09:46:04 CST 2024, time=2024-08-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2208012, encodeId=4e6122080127a, content=审稿速度:1.0 经验分享：投eClinicalMedicine被transfer到iScience，2天送审，2周all reviews complete, 当天major revision，自认为是10分左右的水平，感觉投这个有些亏，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Mon Jun 03 09:34:00 CST 2024, time=2024-06-03, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2214702, encodeId=e1f52214e026c, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;药物 经验分享：2024.4.28投稿，2024.6.6给了大修，两个审稿人，给了20个左右意见，让补meta，2024.6.23修回，2024.7.8小修，只有一个审稿人提了一个小问题，2024.7.11修回，2024.7.13all reviews complete，等待ing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1426565191, createdName=ms4000000921584140, createdTime=Sat Jul 13 08:24:35 CST 2024, time=2024-07-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2211673, encodeId=c2fc22116e3a2, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：记得当初说是对比nc和sa的综合性期刊，现在怎么看怎么像个骗局，连communications xx系列都比不上。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Wed Jun 26 08:15:16 CST 2024, time=2024-06-26, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2210803, encodeId=72da22108032d, content=2023年IF 4.6分。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Thu Jun 20 14:07:08 CST 2024, time=2024-06-20, status=1, ipAttribution=湖北省)]

2024-04-06 ms6000000307870975 来自北京

审稿速度:6.0 | 投稿命中率:50.0
偏重的研究方向：生态学
经验分享：2023年8月投稿
2023年11月第一轮给了大修
2024年2月28日修回
2024年3月20日pre-accept
2024年3月26日格式修改修回
2024年4月1日 with editor。。。

81 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2226178, encodeId=80e922261e84f, content=感觉这个期刊录用率只有1/8<a href='/topic/show?id=fe61688e88d' target=_blank style='color:#2F92EE;'>#生信#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68878, encryptionId=fe61688e88d, topicName=生信)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Tue Sep 17 09:53:34 CST 2024, time=2024-09-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2222643, encodeId=0060222264320, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：分子生物 经验分享：all reviews complete要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7df6548400, createdName=ms2000000368944021, createdTime=Tue Aug 27 12:01:03 CST 2024, time=2024-08-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2197148, encodeId=4d91219e148fc, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：生态学 经验分享：2023年8月投稿 2023年11月第一轮给了大修 2024年2月28日修回 2024年3月20日pre-accept 2024年3月26日格式修改修回 2024年4月1日 with editor。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce406162649, createdName=ms6000000307870975, createdTime=Sat Apr 06 17:20:10 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2097728, encodeId=dd63209e7287c, content=审稿速度:6.0 经验分享：7.14投的，快三个月了，还没修回意见，太慢了，捉急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb028255336, createdName=ms6000000988225388, createdTime=Tue Nov 01 03:41:58 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2218386, encodeId=4487221838675, content=偏重的研究方向：免疫学;医学综合 经验分享：iscience和biomed pharma，或者life science相比，哪个会更好些, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sun Aug 04 08:29:43 CST 2024, time=2024-08-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2218255, encodeId=e040221825573, content=偏重的研究方向：免疫学;生物大分子;医学综合 经验分享：iScience在with editor之后的状态是什么？直接是Under Review？有没有投过综述的大佬？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sat Aug 03 09:46:04 CST 2024, time=2024-08-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2208012, encodeId=4e6122080127a, content=审稿速度:1.0 经验分享：投eClinicalMedicine被transfer到iScience，2天送审，2周all reviews complete, 当天major revision，自认为是10分左右的水平，感觉投这个有些亏，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Mon Jun 03 09:34:00 CST 2024, time=2024-06-03, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2214702, encodeId=e1f52214e026c, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;药物 经验分享：2024.4.28投稿，2024.6.6给了大修，两个审稿人，给了20个左右意见，让补meta，2024.6.23修回，2024.7.8小修，只有一个审稿人提了一个小问题，2024.7.11修回，2024.7.13all reviews complete，等待ing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1426565191, createdName=ms4000000921584140, createdTime=Sat Jul 13 08:24:35 CST 2024, time=2024-07-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2211673, encodeId=c2fc22116e3a2, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：记得当初说是对比nc和sa的综合性期刊，现在怎么看怎么像个骗局，连communications xx系列都比不上。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Wed Jun 26 08:15:16 CST 2024, time=2024-06-26, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2210803, encodeId=72da22108032d, content=2023年IF 4.6分。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Thu Jun 20 14:07:08 CST 2024, time=2024-06-20, status=1, ipAttribution=湖北省)]

2022-11-01 ms6000000988225388

审稿速度:6.0
经验分享：7.14投的，快三个月了，还没修回意见，太慢了，捉急

114 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2226178, encodeId=80e922261e84f, content=感觉这个期刊录用率只有1/8<a href='/topic/show?id=fe61688e88d' target=_blank style='color:#2F92EE;'>#生信#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68878, encryptionId=fe61688e88d, topicName=生信)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Tue Sep 17 09:53:34 CST 2024, time=2024-09-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2222643, encodeId=0060222264320, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：分子生物 经验分享：all reviews complete要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7df6548400, createdName=ms2000000368944021, createdTime=Tue Aug 27 12:01:03 CST 2024, time=2024-08-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2197148, encodeId=4d91219e148fc, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：生态学 经验分享：2023年8月投稿 2023年11月第一轮给了大修 2024年2月28日修回 2024年3月20日pre-accept 2024年3月26日格式修改修回 2024年4月1日 with editor。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce406162649, createdName=ms6000000307870975, createdTime=Sat Apr 06 17:20:10 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2097728, encodeId=dd63209e7287c, content=审稿速度:6.0 经验分享：7.14投的，快三个月了，还没修回意见，太慢了，捉急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb028255336, createdName=ms6000000988225388, createdTime=Tue Nov 01 03:41:58 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2218386, encodeId=4487221838675, content=偏重的研究方向：免疫学;医学综合 经验分享：iscience和biomed pharma，或者life science相比，哪个会更好些, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sun Aug 04 08:29:43 CST 2024, time=2024-08-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2218255, encodeId=e040221825573, content=偏重的研究方向：免疫学;生物大分子;医学综合 经验分享：iScience在with editor之后的状态是什么？直接是Under Review？有没有投过综述的大佬？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sat Aug 03 09:46:04 CST 2024, time=2024-08-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2208012, encodeId=4e6122080127a, content=审稿速度:1.0 经验分享：投eClinicalMedicine被transfer到iScience，2天送审，2周all reviews complete, 当天major revision，自认为是10分左右的水平，感觉投这个有些亏，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Mon Jun 03 09:34:00 CST 2024, time=2024-06-03, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2214702, encodeId=e1f52214e026c, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;药物 经验分享：2024.4.28投稿，2024.6.6给了大修，两个审稿人，给了20个左右意见，让补meta，2024.6.23修回，2024.7.8小修，只有一个审稿人提了一个小问题，2024.7.11修回，2024.7.13all reviews complete，等待ing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1426565191, createdName=ms4000000921584140, createdTime=Sat Jul 13 08:24:35 CST 2024, time=2024-07-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2211673, encodeId=c2fc22116e3a2, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：记得当初说是对比nc和sa的综合性期刊，现在怎么看怎么像个骗局，连communications xx系列都比不上。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Wed Jun 26 08:15:16 CST 2024, time=2024-06-26, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2210803, encodeId=72da22108032d, content=2023年IF 4.6分。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Thu Jun 20 14:07:08 CST 2024, time=2024-06-20, status=1, ipAttribution=湖北省)]

2024-08-04 少吃一口来自四川省

偏重的研究方向：免疫学;医学综合
经验分享：iscience和biomed pharma，或者life science相比，哪个会更好些

0 0

[GetPortalCommentsPageByObjectIdResponse(id=2226178, encodeId=80e922261e84f, content=感觉这个期刊录用率只有1/8<a href='/topic/show?id=fe61688e88d' target=_blank style='color:#2F92EE;'>#生信#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68878, encryptionId=fe61688e88d, topicName=生信)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Tue Sep 17 09:53:34 CST 2024, time=2024-09-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2222643, encodeId=0060222264320, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：分子生物 经验分享：all reviews complete要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7df6548400, createdName=ms2000000368944021, createdTime=Tue Aug 27 12:01:03 CST 2024, time=2024-08-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2197148, encodeId=4d91219e148fc, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：生态学 经验分享：2023年8月投稿 2023年11月第一轮给了大修 2024年2月28日修回 2024年3月20日pre-accept 2024年3月26日格式修改修回 2024年4月1日 with editor。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce406162649, createdName=ms6000000307870975, createdTime=Sat Apr 06 17:20:10 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2097728, encodeId=dd63209e7287c, content=审稿速度:6.0 经验分享：7.14投的，快三个月了，还没修回意见，太慢了，捉急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb028255336, createdName=ms6000000988225388, createdTime=Tue Nov 01 03:41:58 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2218386, encodeId=4487221838675, content=偏重的研究方向：免疫学;医学综合 经验分享：iscience和biomed pharma，或者life science相比，哪个会更好些, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sun Aug 04 08:29:43 CST 2024, time=2024-08-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2218255, encodeId=e040221825573, content=偏重的研究方向：免疫学;生物大分子;医学综合 经验分享：iScience在with editor之后的状态是什么？直接是Under Review？有没有投过综述的大佬？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sat Aug 03 09:46:04 CST 2024, time=2024-08-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2208012, encodeId=4e6122080127a, content=审稿速度:1.0 经验分享：投eClinicalMedicine被transfer到iScience，2天送审，2周all reviews complete, 当天major revision，自认为是10分左右的水平，感觉投这个有些亏，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Mon Jun 03 09:34:00 CST 2024, time=2024-06-03, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2214702, encodeId=e1f52214e026c, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;药物 经验分享：2024.4.28投稿，2024.6.6给了大修，两个审稿人，给了20个左右意见，让补meta，2024.6.23修回，2024.7.8小修，只有一个审稿人提了一个小问题，2024.7.11修回，2024.7.13all reviews complete，等待ing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1426565191, createdName=ms4000000921584140, createdTime=Sat Jul 13 08:24:35 CST 2024, time=2024-07-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2211673, encodeId=c2fc22116e3a2, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：记得当初说是对比nc和sa的综合性期刊，现在怎么看怎么像个骗局，连communications xx系列都比不上。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Wed Jun 26 08:15:16 CST 2024, time=2024-06-26, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2210803, encodeId=72da22108032d, content=2023年IF 4.6分。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Thu Jun 20 14:07:08 CST 2024, time=2024-06-20, status=1, ipAttribution=湖北省)]

2024-08-03 少吃一口来自四川省

偏重的研究方向：免疫学;生物大分子;医学综合
经验分享：iScience在with editor之后的状态是什么？直接是Under Review？有没有投过综述的大佬？

49 0

[GetPortalCommentsPageByObjectIdResponse(id=2226178, encodeId=80e922261e84f, content=感觉这个期刊录用率只有1/8<a href='/topic/show?id=fe61688e88d' target=_blank style='color:#2F92EE;'>#生信#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68878, encryptionId=fe61688e88d, topicName=生信)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Tue Sep 17 09:53:34 CST 2024, time=2024-09-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2222643, encodeId=0060222264320, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：分子生物 经验分享：all reviews complete要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7df6548400, createdName=ms2000000368944021, createdTime=Tue Aug 27 12:01:03 CST 2024, time=2024-08-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2197148, encodeId=4d91219e148fc, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：生态学 经验分享：2023年8月投稿 2023年11月第一轮给了大修 2024年2月28日修回 2024年3月20日pre-accept 2024年3月26日格式修改修回 2024年4月1日 with editor。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce406162649, createdName=ms6000000307870975, createdTime=Sat Apr 06 17:20:10 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2097728, encodeId=dd63209e7287c, content=审稿速度:6.0 经验分享：7.14投的，快三个月了，还没修回意见，太慢了，捉急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb028255336, createdName=ms6000000988225388, createdTime=Tue Nov 01 03:41:58 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2218386, encodeId=4487221838675, content=偏重的研究方向：免疫学;医学综合 经验分享：iscience和biomed pharma，或者life science相比，哪个会更好些, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sun Aug 04 08:29:43 CST 2024, time=2024-08-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2218255, encodeId=e040221825573, content=偏重的研究方向：免疫学;生物大分子;医学综合 经验分享：iScience在with editor之后的状态是什么？直接是Under Review？有没有投过综述的大佬？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sat Aug 03 09:46:04 CST 2024, time=2024-08-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2208012, encodeId=4e6122080127a, content=审稿速度:1.0 经验分享：投eClinicalMedicine被transfer到iScience，2天送审，2周all reviews complete, 当天major revision，自认为是10分左右的水平，感觉投这个有些亏，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Mon Jun 03 09:34:00 CST 2024, time=2024-06-03, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2214702, encodeId=e1f52214e026c, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;药物 经验分享：2024.4.28投稿，2024.6.6给了大修，两个审稿人，给了20个左右意见，让补meta，2024.6.23修回，2024.7.8小修，只有一个审稿人提了一个小问题，2024.7.11修回，2024.7.13all reviews complete，等待ing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1426565191, createdName=ms4000000921584140, createdTime=Sat Jul 13 08:24:35 CST 2024, time=2024-07-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2211673, encodeId=c2fc22116e3a2, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：记得当初说是对比nc和sa的综合性期刊，现在怎么看怎么像个骗局，连communications xx系列都比不上。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Wed Jun 26 08:15:16 CST 2024, time=2024-06-26, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2210803, encodeId=72da22108032d, content=2023年IF 4.6分。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Thu Jun 20 14:07:08 CST 2024, time=2024-06-20, status=1, ipAttribution=湖北省)]

2024-06-03 ms4000001339792170 来自湖北省

审稿速度:1.0
经验分享：投eClinicalMedicine被transfer到iScience，2天送审，2周all reviews complete, 当天major revision，自认为是10分左右的水平，感觉投这个有些亏，，，

66 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2226178, encodeId=80e922261e84f, content=感觉这个期刊录用率只有1/8<a href='/topic/show?id=fe61688e88d' target=_blank style='color:#2F92EE;'>#生信#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68878, encryptionId=fe61688e88d, topicName=生信)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Tue Sep 17 09:53:34 CST 2024, time=2024-09-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2222643, encodeId=0060222264320, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：分子生物 经验分享：all reviews complete要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7df6548400, createdName=ms2000000368944021, createdTime=Tue Aug 27 12:01:03 CST 2024, time=2024-08-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2197148, encodeId=4d91219e148fc, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：生态学 经验分享：2023年8月投稿 2023年11月第一轮给了大修 2024年2月28日修回 2024年3月20日pre-accept 2024年3月26日格式修改修回 2024年4月1日 with editor。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce406162649, createdName=ms6000000307870975, createdTime=Sat Apr 06 17:20:10 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2097728, encodeId=dd63209e7287c, content=审稿速度:6.0 经验分享：7.14投的，快三个月了，还没修回意见，太慢了，捉急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb028255336, createdName=ms6000000988225388, createdTime=Tue Nov 01 03:41:58 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2218386, encodeId=4487221838675, content=偏重的研究方向：免疫学;医学综合 经验分享：iscience和biomed pharma，或者life science相比，哪个会更好些, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sun Aug 04 08:29:43 CST 2024, time=2024-08-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2218255, encodeId=e040221825573, content=偏重的研究方向：免疫学;生物大分子;医学综合 经验分享：iScience在with editor之后的状态是什么？直接是Under Review？有没有投过综述的大佬？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sat Aug 03 09:46:04 CST 2024, time=2024-08-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2208012, encodeId=4e6122080127a, content=审稿速度:1.0 经验分享：投eClinicalMedicine被transfer到iScience，2天送审，2周all reviews complete, 当天major revision，自认为是10分左右的水平，感觉投这个有些亏，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Mon Jun 03 09:34:00 CST 2024, time=2024-06-03, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2214702, encodeId=e1f52214e026c, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;药物 经验分享：2024.4.28投稿，2024.6.6给了大修，两个审稿人，给了20个左右意见，让补meta，2024.6.23修回，2024.7.8小修，只有一个审稿人提了一个小问题，2024.7.11修回，2024.7.13all reviews complete，等待ing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1426565191, createdName=ms4000000921584140, createdTime=Sat Jul 13 08:24:35 CST 2024, time=2024-07-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2211673, encodeId=c2fc22116e3a2, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：记得当初说是对比nc和sa的综合性期刊，现在怎么看怎么像个骗局，连communications xx系列都比不上。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Wed Jun 26 08:15:16 CST 2024, time=2024-06-26, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2210803, encodeId=72da22108032d, content=2023年IF 4.6分。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Thu Jun 20 14:07:08 CST 2024, time=2024-06-20, status=1, ipAttribution=湖北省)]

2024-07-13 ms4000000921584140 来自山东省

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤;药物
经验分享：2024.4.28投稿，2024.6.6给了大修，两个审稿人，给了20个左右意见，让补meta，2024.6.23修回，2024.7.8小修，只有一个审稿人提了一个小问题，2024.7.11修回，2024.7.13all reviews complete，等待ing

66 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2226178, encodeId=80e922261e84f, content=感觉这个期刊录用率只有1/8<a href='/topic/show?id=fe61688e88d' target=_blank style='color:#2F92EE;'>#生信#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68878, encryptionId=fe61688e88d, topicName=生信)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Tue Sep 17 09:53:34 CST 2024, time=2024-09-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2222643, encodeId=0060222264320, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：分子生物 经验分享：all reviews complete要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7df6548400, createdName=ms2000000368944021, createdTime=Tue Aug 27 12:01:03 CST 2024, time=2024-08-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2197148, encodeId=4d91219e148fc, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：生态学 经验分享：2023年8月投稿 2023年11月第一轮给了大修 2024年2月28日修回 2024年3月20日pre-accept 2024年3月26日格式修改修回 2024年4月1日 with editor。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce406162649, createdName=ms6000000307870975, createdTime=Sat Apr 06 17:20:10 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2097728, encodeId=dd63209e7287c, content=审稿速度:6.0 经验分享：7.14投的，快三个月了，还没修回意见，太慢了，捉急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb028255336, createdName=ms6000000988225388, createdTime=Tue Nov 01 03:41:58 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2218386, encodeId=4487221838675, content=偏重的研究方向：免疫学;医学综合 经验分享：iscience和biomed pharma，或者life science相比，哪个会更好些, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sun Aug 04 08:29:43 CST 2024, time=2024-08-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2218255, encodeId=e040221825573, content=偏重的研究方向：免疫学;生物大分子;医学综合 经验分享：iScience在with editor之后的状态是什么？直接是Under Review？有没有投过综述的大佬？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sat Aug 03 09:46:04 CST 2024, time=2024-08-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2208012, encodeId=4e6122080127a, content=审稿速度:1.0 经验分享：投eClinicalMedicine被transfer到iScience，2天送审，2周all reviews complete, 当天major revision，自认为是10分左右的水平，感觉投这个有些亏，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Mon Jun 03 09:34:00 CST 2024, time=2024-06-03, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2214702, encodeId=e1f52214e026c, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;药物 经验分享：2024.4.28投稿，2024.6.6给了大修，两个审稿人，给了20个左右意见，让补meta，2024.6.23修回，2024.7.8小修，只有一个审稿人提了一个小问题，2024.7.11修回，2024.7.13all reviews complete，等待ing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1426565191, createdName=ms4000000921584140, createdTime=Sat Jul 13 08:24:35 CST 2024, time=2024-07-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2211673, encodeId=c2fc22116e3a2, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：记得当初说是对比nc和sa的综合性期刊，现在怎么看怎么像个骗局，连communications xx系列都比不上。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Wed Jun 26 08:15:16 CST 2024, time=2024-06-26, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2210803, encodeId=72da22108032d, content=2023年IF 4.6分。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Thu Jun 20 14:07:08 CST 2024, time=2024-06-20, status=1, ipAttribution=湖北省)]

2024-06-26 山蛙来自河南省

审稿速度:2.0 | 投稿命中率:50.0
经验分享：记得当初说是对比nc和sa的综合性期刊，现在怎么看怎么像个骗局，连communications xx系列都比不上。

76 0

[GetPortalCommentsPageByObjectIdResponse(id=2226178, encodeId=80e922261e84f, content=感觉这个期刊录用率只有1/8<a href='/topic/show?id=fe61688e88d' target=_blank style='color:#2F92EE;'>#生信#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68878, encryptionId=fe61688e88d, topicName=生信)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0ea8286723, createdName=ms3000000851999119, createdTime=Tue Sep 17 09:53:34 CST 2024, time=2024-09-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2222643, encodeId=0060222264320, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：分子生物 经验分享：all reviews complete要多久呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7df6548400, createdName=ms2000000368944021, createdTime=Tue Aug 27 12:01:03 CST 2024, time=2024-08-27, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2197148, encodeId=4d91219e148fc, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：生态学 经验分享：2023年8月投稿 2023年11月第一轮给了大修 2024年2月28日修回 2024年3月20日pre-accept 2024年3月26日格式修改修回 2024年4月1日 with editor。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=81, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce406162649, createdName=ms6000000307870975, createdTime=Sat Apr 06 17:20:10 CST 2024, time=2024-04-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2097728, encodeId=dd63209e7287c, content=审稿速度:6.0 经验分享：7.14投的，快三个月了，还没修回意见，太慢了，捉急, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb028255336, createdName=ms6000000988225388, createdTime=Tue Nov 01 03:41:58 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2218386, encodeId=4487221838675, content=偏重的研究方向：免疫学;医学综合 经验分享：iscience和biomed pharma，或者life science相比，哪个会更好些, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sun Aug 04 08:29:43 CST 2024, time=2024-08-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2218255, encodeId=e040221825573, content=偏重的研究方向：免疫学;生物大分子;医学综合 经验分享：iScience在with editor之后的状态是什么？直接是Under Review？有没有投过综述的大佬？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Sat Aug 03 09:46:04 CST 2024, time=2024-08-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2208012, encodeId=4e6122080127a, content=审稿速度:1.0 经验分享：投eClinicalMedicine被transfer到iScience，2天送审，2周all reviews complete, 当天major revision，自认为是10分左右的水平，感觉投这个有些亏，，，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Mon Jun 03 09:34:00 CST 2024, time=2024-06-03, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2214702, encodeId=e1f52214e026c, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;药物 经验分享：2024.4.28投稿，2024.6.6给了大修，两个审稿人，给了20个左右意见，让补meta，2024.6.23修回，2024.7.8小修，只有一个审稿人提了一个小问题，2024.7.11修回，2024.7.13all reviews complete，等待ing, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1426565191, createdName=ms4000000921584140, createdTime=Sat Jul 13 08:24:35 CST 2024, time=2024-07-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2211673, encodeId=c2fc22116e3a2, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：记得当初说是对比nc和sa的综合性期刊，现在怎么看怎么像个骗局，连communications xx系列都比不上。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/09/26/41d1186db3b6c462bcb8e33954e97968.jpg, createdBy=a95e2575777, createdName=山蛙, createdTime=Wed Jun 26 08:15:16 CST 2024, time=2024-06-26, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2210803, encodeId=72da22108032d, content=2023年IF 4.6分。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=eb475493456, createdName=ms4000001339792170, createdTime=Thu Jun 20 14:07:08 CST 2024, time=2024-06-20, status=1, ipAttribution=湖北省)]

2024-06-20 ms4000001339792170 来自湖北省

2023年IF 4.6分。。。。

87 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务